A total of 8 obese subjects with type 2 diabetes were studied while on a eucaloric diet and after reduced energy intake (25 and then 75% of requirements for 10 days each). Weight loss was 2, 3, and 3 kg after 5, 10, and 20 days, respectively; all of the weight lost was body fat. Fasting blood glucose (FBG) levels fell from 11.9 ± 1.4 at baseline to 8.9 ± 1.6, 7.9 ± 1.4, and 8.8 ± 1.3 mmol/l at days 5, 10, and 20, respectively (P < 0.05, baseline vs. 5, 10, and 20 days). Endogenous glucose production (EGP) was 22 ± 2, 18 ± 2, 17 ± 2, and 22 ± 2 µmol · kg -1 lean body mass (LBM) · min -1 (P < 0.05, days 5 and 10 vs. baseline). Gluconeogenesis measured by mass isotopomer distribution analysis provided 31 ± 4, 41 ± 5, 40 ± 4, and 33 ± 4%, respectively, of the EGP (NS); absolute glycogenolytic contribution to the EGP was 15 ± 2, 11 ± 2, 11 ± 2, and 15 ± 2 µmol · kg -1 LBM · min -1 , respectively (P < 0.001, baseline vs. days 5 and 10 and day 10 vs. day 20). The blood glucose clearance rate increased significantly at day 20 (P < 0.05). Neither lipolysis nor flux of plasma nonesterified fatty acids were altered compared with baseline. In conclusion, severe energy restriction per se independent of major changes in body composition reduces both FBG concentration and EGP in type 2 diabetes, the reduction in EGP results entirely from a reduction of glycogenolytic input into blood glucose, and the duration of reduced glycogenolysis is short-lived after relaxation of energy restriction even without weight gain, but effects on plasma glucose clearance persist and partially maintain the improvement in fasting glycemia. Diabetes 49:1691-1699, 2000 D ietary restriction of total energy intake has been shown to influence fasting blood glucose (FBG) and endogenous glucose production (EGP) before significant changes in body weight or composition occur (1-3). The changes in FBG and EGP are correlated, and most of the effects are seen within 7-10 days of starting caloric restriction (3,4).
D
ietary restriction of total energy intake has been shown to influence fasting blood glucose (FBG) and endogenous glucose production (EGP) before significant changes in body weight or composition occur (1) (2) (3) . The changes in FBG and EGP are correlated, and most of the effects are seen within 7-10 days of starting caloric restriction (3, 4) .
The glucose-producing pathways affected by energy restriction remain uncertain. Glycogenolysis and gluconeogenesis both contribute to EGP in the postabsorptive state. In nondiabetic humans and rodents, starvation or carbohydraterestricted diets reduce EGP (5, 6) ; in rats, the change in EGP results entirely from reduced glycogenolytic flux to glucose, not reduced gluconeogenesis input. Some previous studies have suggested that predominantly gluconeogenesis is increased in type 2 diabetes, whereas other results suggest that the primary contribution to EGP is from hepatic glycogenolysis (7) (8) (9) . FBG could also be reduced by energy restriction if the metabolic clearance of glucose were increased. This could be reflected in either increased oxidative or nonoxidative disposal of glucose under fasting conditions.
Our laboratory has previously shown that fractional and absolute gluconeogenesis can be measured in rats and in humans by infusing [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] C 1 ]glycerol and [U- 13 C 6 ]glucose using mass isotopomer distribution analysis (MIDA) to measure the fractional gluconeogenesis contribution to EGP (5, 10) . We investigated the metabolic mechanisms by which dietary energy restriction reduces EGP and FBG in obese type 2 diabetes subjects and whether metabolic changes during energy restriction relate to body composition changes or energy balance per se. Some of these results have previously been presented in abstract form (11, 12) .
phase was a 5-day eucaloric baseline period. An estimated weight-maintaining (eucaloric) diet was determined for each subject based on body weight and diet records taken by the dietitians in the GCRC. The average composition of this diet was 18% protein, 35% fat, and 47% carbohydrate. The total energy content of the diet was adjusted if the subject's daily weight was not stable during the 5-day baseline period in the GCRC. The second phase consisted of 10 days of dietary energy restriction to 25% of eucaloric needs (30% protein, 9% fat, 61% carbohydrate). This was followed by the third and final phase in which 75% of eucaloric needs (20% protein, 30% fat, and 50% carbohydrate) were provided for the final 10 days. Isotope infusion studies with indirect calorimetry were performed 4 times: at baseline (after documented weight stabilization, day 5 of the GCRC admission) and at 5, 10, and 20 days after beginning the dietary intervention.
Subjects ate dinner at 1800 the night before each infusion study and remained fasting until the infusion studies were completed at 0900 the next day. Intravenous lines (both antecubital spaces) were started at 2200 and kept open with 0.45% saline. At 0200, a primed/continuous low-dose infusion of [U- 13 C 6 ]glucose (6.7 µmol/kg prime, 0.11 µmol · kg -1 · min -1 ) was started ( Fig. 1B) . At 0500, [1,2,3,4-13 C 4 ]palmitate (27 nmol · kg -1 · min -1 ) mixed with human serum albumin and [2-13 C 1 ]glycerol (2.7 µmol · kg -1 lean body mass (LBM) · min -1 ) was started. Blood was drawn at 0800, 0830, 0840, 0850, and 0900. Blood samples were collected in chilled tubes containing EDTA and were spun; plasma was stored at -20°C until analysis. Indirect calorimetry was performed between 0830 and 0900 using a Deltatrac unit with a ventilated hood (Sensor Medics, Yorba Linda, CA). Body composition was assessed by bioelectrical impedance analysis (BIA) (RJL, Clinton Township, MI). Analytical methods. Glucose was isolated from deproteinized plasma by ion exchange chromatography and derivatized in pyridine:acetic anhydride to glucose penta-acetate (10) . Derivatives were analyzed by chemical ionization gas chromatography/mass spectrometry (GC/MS) using an HP Model 5971 instrument (Hewlett-Packard, Palo Alto, CA) under selected ion recording (SIR). A DB-17 fused silica column (60 m, 0.25 mm internal diameter) at 260°C was used. For glucose penta-acetate, m/z 331-333 and 337 were monitored. Glycerol was isolated from plasma by ion exchange chromatography (10), per-acetylated in pyridine:acetic anhydride, and analyzed by GC/MS (DB-225 column) by chemical ionization under SIR monitoring of m/z 159 and 160. Standard curves were constructed using the same stable isotope-labeled materials that were administered to subjects. Then 1 ml plasma was extracted immediately after blood collection for analysis of nonesterified fatty acid (NEFA) using 4 ml 30:70 heptane-isopropanol containing 100 nmol pentadecanoic acid as an internal standard. NEFA was isolated from the extraction mixture and was separated from cholesterol and phospholipids on silica gel G thin-layer chromatography plates. Fatty acids were scraped from the plates and were derivatized with boron trichloride-methanol to form fatty acid methyl esters that were analyzed by GC/MS using a 12.0-m DB-1 fused silica column with electron impact ionization under SIR monitoring of m/z 270-274. Concentrations of individual fatty acids were determined simultaneously by using a splitter that diverted a portion of the gas chromatography effluent to a flame ionization detector. Plasma and urine glucose concentrations were determined with a YSI glucose analyzer (Yellow Springs, OH). Urea nitrogen was calculated by the Kjeldahl method. Stable isotope-labeled compounds were purchased from Isotec (Miamisburg, OH) or Cambridge Isotopes (Somerville, MA) and were >99% enriched. Calculations. The rate of appearance (R a ) of plasma glucose was calculated by dilution (6, 10) :
where I glucose is the rate of infusion of the [U- 13 C 6 ]glucose tracer, and M 6 -glucose (ME) is the molar fraction of [U- 13 C 6 ]glucose, calculated by comparison with true standards. Under the fasting conditions present during these infusion studies, EGP is then calculated as follows:
The fraction of blood glucose that was synthesized by the gluconeogenesis pathway ( f glucose ) was calculated by MIDA (6):
where EM 1 -glucose is the measured ME of the M 1 isotopomer of glucose, and A 1 ∞ -glucose is the calculated asymptotic M 1 glucose enrichment possible from the triose-phosphate precursor pool enrichment present (6) . Absolute gluconeogenesis was then calculated from the glucose flux multiplied by the f glucose from gluconeogenesis:
The absolute contribution to glucose from glycogen was calculated by difference:
absolute contribution of glycogen to EGP = EGP -absolute gluconeogenesis
The endogenous rate of appearance of glycerol (R a glycerol) was calculated by dilution: (6) where I glycerol is the rate of infusion of labeled glycerol and M 1 -glycerol (ME) is the molar fraction of [2-
13
C 1 ] glycerol calculated by comparison to true standards. The rate of appearance of NEFA (R a NEFA) was calculated by dilution:
where I palmitate is the rate of infusion of labeled palmitate and M 4 -palmitate (ME) is the molar fraction of the [ Substrate oxidation rates were calculated by indirect calorimetry using the equations of Jequier et al. (13) . Fat oxidation was converted from milligrams per minute to micromoles per minute by assuming that the average molecular weight of plasma NEFA is ~270 g/mol.
Plasma glucose clearance was calculated as the rate of disappearance of glucose (identical to R a glucose under steady-state conditions) divided by the plasma glucose concentration:
The contribution to gluconeogenesis from labeled glycerol carbon was calculated from the precursor-product relationship (5) Proportion of gluconeogenesis derived from plasma glycerol (%) = [gluconeogenesis precursor pool enrichment (ME)/ plasma glycerol enrichment (ME)] ϫ 100 (9) Statistical analysis. Data are means ± SE. Repeated-measures analysis of variance was used to test for statistical significance with significance set at P ≤ 0.05. Post hoc analysis (follow-up testing) was performed using Tukey's t test on a mainframe computer (SPSS software; Chicago).
RESULTS

Body composition.
Weight by phase is shown in Table 1 . Average weight loss during the first 5 days of phase 1 (25% of eucaloric requirements) was 1.84 ± 0.29 kg, and, after another 5 days, total weight loss was 3.04 ± 0.52 kg. Despite energy restriction to 75% of eucaloric needs between days 10 and 20, no further weight loss was documented. The average weight at day 5 was significantly different from that at baseline, and day 10 was statistically different from day 5 but not different from day 20. All of the weight loss involved a loss of body fat based on BIA measurements; fat-free mass did not change (Table 1) . Carbohydrate metabolism. As seen in Table 2 , FBG fell by day 5 and remained significantly lower than baseline throughout the study. The decrease in FBG was associated with a significant decrease in EGP at days 5 and 10 but a return to the baseline EGP values at day 20. The absolute flux of gluconeogenesis into blood glucose did not change; all of the changes in EGP were because of altered contributions from glycogen to blood glucose. The proportion of gluconeogenesis derived from labeled plasma glycerol carbon did not change by phase (32 ± 3, 34 ± 3, 33 ± 2, and 33 ± 4% from baseline and days 5, 10, and 20, respectively). For each subject, by phase, the values for EM 1 -glucose and EM 2 -glucose, the calculated hepatic triose-phosphate precursor pool enrichments (p), and f glucose are shown in Table 3 . Plasma glucose clearance was 2.0 ± 0.2, 2.1 ± 0.2, 2.3 ± 0.3, and 2.7 ± 0.3 ml · kg -1 LBM · min -1 at baseline and at days 5, 10, and 20, respectively (P < 0.05, day 20 vs. baseline and day 20 vs. day 5). Lipid metabolism. Neither R a NEFA nor R a glycerol varied by phase (Table 2) . Whole-body lipid oxidation was 7.6 ± 0.6, 8.5 ± 0.4, 7.8 ± 0.3, and 6.8 ± 0.6 µmol · kg -1 LBM · min -1 at baseline and at days 5, 10, and 20, respectively (significant difference between days 5 and 20). The nonprotein respiratory quotient did not change significantly between phases (0.74 ± 0.01, 0.71 ± 0.01, 0.71 ± 0.02, and 0.74 ± 0.01, respectively). Fasting plasma triglyceride concentrations were 221 ± 122, 121 ± 38, 106 ± 35, and 150 ± 61 mg/dl, respectively (NS between phases). Plasma NEFA concentrations were 500 ± 80, 800 ± 170, 830 ± 90, and 500 ± 120 µmol/l, respectively (P < 0.05 day 10 vs. baseline and day 20).
DISCUSSION
Previous studies (1) (2) (3) 14) have shown that the reduction in FBG during energy restriction in type 2 diabetes often occurs within the first week, before major alterations in body weight; that the reduction in FBG during energy restriction correlates closely with reduced EGP; and that relaxation of caloric restriction without weight gain is associated with a return to elevated FBG and EGP levels. The new observations in our study relate to the underlying metabolic changes, including the sources of EGP and the effects on fatty acid metabolism. Our major findings were that the rapid reduction in EGP resulted entirely from a decreased contribution from glycogenolysis with no change in absolute gluconeogenesis; that the effects on glycogenolysis and EGP were reversed rapidly by relaxation of the degree of energy restriction, even though the diet remained hypocaloric; that FBG remained reduced from baseline after relaxation of the energy restriction because of increased plasma glucose clearance; and that high rates of lipolysis and fat oxidation present at baseline did not increase further with energy restriction.
EGP has 2 sources of metabolic input in the postabsorptive state: glycogenolysis and gluconeogenesis. Our fractional gluconeogenesis results in 8 individuals with type 2 diabetes were lower at the baseline measurement than those published by Magnusson et al. (7) using nuclear magnetic resonance (NMR) spectroscopy, although our findings were similar to older estimates based on splanchnic arteriovenous differences in type 2 diabetes (15) . Potential difficulties in using 13 C-glycerol for MIDA calculations have been suggested (16, 17) . This and several factors relating to the isotope infusion protocol and analytical approach may affect these measurements. Reviewing the potential effect of these factors in detail is therefore worthwhile. We have recently published a more general review of MIDA, including potential limitations, based on our experience during the past 8 years (18) .
The first issue relating to experimental design is the optimal duration for labeled glucose and glycerol infusions. Other groups have previously reported (19, 20) that up to 7-10 h of labeled glucose administration may be necessary to reach plateau-specific activities in plasma glucose in severely hyperglycemic subjects (glucose >250 mg/dl). The time required for equilibration in subjects with normoglycemia or modest hyperglycemia (<200 mg/dl), as was present in our subjects, was considerably shorter (i.e., <6 h) (19) . We thus provided a 7-h infusion of labeled glucose. In contrast, our infusion time for [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] C 1 ]glycerol was designed to be only 4 h for several reasons. First, we anticipated that plasma glucose enrichments would have reached nearly plateau values after 4 h based on studies in modestly hyperglycemic diabetic subjects (19) . The enrichments of plasma glucose at 4 h were measured at each phase of the study, and the values were 86 ± 3, 86 ± 2, 89 ± 3, and 89 ± 2% of the 7-h values at days 0, 5, 10, and 20, respectively. This suggests that fractional gluconeogenesis may have been underestimated by, at most, a factor of 11-14% (i.e., a 3-5% change in the contribution from gluconeogenesis) because of a 4-h infusion, but this result is not altered by phase (and therefore is unlikely to affect our conclusions about the effects of energy restriction on sources of glucose). Second, the delayed plateau in glucose labeling may reflect cycling of blood glucose through liver glycogen and back into the bloodstream (glycogen cycling) (21) (22) (23) (24) (25) . The measurement and interpretation of glycogen cycling has been discussed in detail by us (23, 24) and others (21, 22) . To the extent that this process occurs, it does not reflect simple gluconeogenesis and is not optimally included in gluconeogenesis estimates (i.e., inclusion results in underestimation of glycogenolysis). It should be noted that the possibility of glycogen cycling is a physiological complicating factor that affects any attempt to measure gluconeogenesis or glycogenolysis, not just the MIDA technique. In the present study, the important question is whether glycogen cycling is affected by energy restriction. The constancy of 7-vs. 4-h values for M 6 glucose enrichments in each phase noted above suggests that significant differences in cycling between phases do not occur. Moreover, the gluconeogenesis precursor infusion was intentionally kept shorter than the labeled glucose infusion to minimize the effect of delayed glycogen cycling on fractional gluconeogenesis estimates. The potential effect of differences in glycogen cycling between phases on gluconeogenesis estimates is modeled in Table 4 .
A second issue relating to isotopic experimental design is whether the gluconeogenesis measurements could be contaminated by the other isotopic labels given ([1,2,3,4- be in the range of 50% (27) . Also, even if oxaloacetate were to leave the tricarboxylic acid cycle before the completion of 1 turn of the cycle, decarboxylation of oxaloacetate to pyruvate results in the loss of 1 of the labeled carbons 50% of the time (27) . Therefore, the maximum enrichment of a doubly labeled triose-phosphate from [1,2,3,4- [U- 13 C 6 ]glucose is another matter. We have given [U- 13 C 6 ]glucose to mice, rats, and humans with and without diabetes. When the plasma M 6 enrichment of glucose is kept at <1%, enrichment of EM 2 -glucose isotopomers is <0.0005 ME (M.K.H., R.A.N., P.A.L., unpublished data). In the present studies, plasma glucose M 6 enrichments were ~0.60-0.80%. This should result in M 2 glucose values <0.0005 or 0.0010 ME, which will not interfere significantly with the calculation of f glucose (simulations are provided in Table 4) .
A third issue is the effect of various metabolic or analytical complicating factors on our estimates of gluconeogenesis. It has been suggested that an isotopic labeling gradient may exist across the liver when labeled glycerol is administered (16, 17) . This conclusion was based on avid uptake of glycerol by the liver and on dilution of labeled glycerol leaving the liver. Depletion of labeled glycerol across the hepatic lobule may limit the delivery of the label to hepatocytes distal along the lobule; a labeling gradient was postulated to explain lower-than-expected values of fractional gluconeogenesis contribution in fasted rats or perfused livers (16, 17) . However, several investigators have reported fractional gluconeogenesis values that were not low (i.e., in the range of 90% or appropriately high fractional contribution) in fasted rats (5, 6, 28) , perfused livers (28), and humans (10, 29, 30) . When labeled glycerol is administered at the rates used in our study (e.g., to achieve hepatic precursor pool enrichments >0.10 ME), gluconeogenesis appears to not be underestimated (5,6,10,28-30), perhaps because the increased glycerol delivery overcomes any potential gradient.
Distinguishing between uptake of a metabolite by a tissue and a metabolic gradient within the tissue is also important. The liver could take up glycerol avidly in many ways without resulting in isotopic inhomogeneity within the tissue (e.g., metabolite mixing in the space of Disse, which is not subject DIABETES, VOL. 49, OCTOBER 2000 1695 Effects of various complicating factors on estimates of p and f glucose for gluconeogenesis were simulated by computer modeling as described previously (18) . Basis of lower-bound, upper-bound, and anticipated (reasonable) estimates are described below. *Contamination of M 2 -triose-p was calculated by adding 0.0005-0.0010 ME to M 2 glucose and back-calculating p and f glucose . Values used for upper and lower estimates and for anticipated estimate are from human subjects given [U- 13 C 6 ]glucose in the fasted state. †Sim-ple glycerol labeling gradient was calculated as described previously (18) . The range was based on maximal likely 13 C-glycerol extraction and measured gluconeogenesis values previously reported for these 13 C-glycerol infusion rates (16) . The gradient was simulated as the sum of 100 steps with the gradient of plasma glycerol contribution to p from 50 to 10% across the lobule (5-fold gradient) or 40 to 20% across the lobule (2-fold gradient) with plasma glycerol enrichment of 0.45 ME (and thus average p = 0.30 ϫ 0.45 ME = 0.135 ME for both simulations). ‡Label exchange into lactate was previously measured to be 25% of the value of p during 13 C -glycerol infusion (6) . Simulation was performed by adding 25% value of p for nonglycerol gluconeogenesis substrates (lactate, alanine, etc.) across the lobule to 13 C-glycerol input as calculated in footnote †. §The biosynthetic gradient was calculated by imposing a gradient of relative contribution to total gluconeogenesis falling from 100:1 across the liver (in steps of 1) paralleling a gradient of label input from plasma 13 C-glycerol (enrichment of 0.45 ME). ʈStimulation of gluconeogenesis was assumed to be identical to an increase in the triose-phosphate pool (i.e., ~10% increase in p attributable to 13 C-glycerol, with 100% of triose-phosphates proceeding to gluconeogenesis), either with no hepatic autoregulation (for upper-bound estimate) or with complete autoregulation (for minimum estimate) and 50% autoregulation (for reasonable estimate). ¶This calculation assumes that a 4-h plateau value represents 95% of true blood equilibrium value and that the increase during hours 4-7 represents mostly isotope cycling from labeled glycogen (21) (22) (23) (24) (25) . A range of 4-vs. 7-h values measured in these subjects is used. #Analytical error estimates were calculated as described previously (18) . The ±2% value represents the actual accuracy criteria that were used for inclusion of GC/MS data in the present study.
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to bulk flow of blood; gap junction communications between hepatocytes along the lobule; or exchange and release of labeled metabolites among cells). Regarding metabolite exchange, we have observed that plasma 13 C-lactate enrichments reach ~25% of values of p during 13 C-glycerol infusions (6) . This labeled lactate/alanine will then tend to dampen any gradients of substrate glycerol uptake across the hepatic lobule. This is another way that complex label behavior works to the benefit of combinatorial (MIDA) methods; the net effect being that all of the 13 C that enters hepatic triose-p during a labeled glycerol infusion need not have entered in the form of 13 C-glycerol, so that extreme labeling gradients are mitigated even if glycerol itself follows a lobular uptake pattern.
Simulating the quantitative effect on gluconeogenesis of various labeling gradients across the hepatic lobule is possible by computer modeling (18) . If a simple gradient of labeled glycerol uptake exists across the lobule (i.e., p begins at 0.18 and ends at 0.09 for an average value of 0.135), then f glucose is only underestimated by 3.8% of the true value (Table 4) . Even if p varies dramatically (by 5-fold from 0.225 to 0.045 with the average value still being 0.135) across the lobule, then f glucose is reduced by 13.3% (Table 4) . Such a severe gradient is unlikely to occur, particularly at the 13 C-glycerol infusion rates herein, for the reasons discussed above, including the mixing of 13 C-label into lactate/alanine pools. If label exchange into these other pools is included in a computer simulation, then even a 5-fold glycerol gradient reduces f glucose only by 8.2% (i.e., to 91.8% of the correct value) (Table 4) .
Finally, one cannot ignore the possibility that a true biosynthetic gradient may also exist that parallels any gradient for label uptake. If most gluconeogenesis as well as label uptake occurs in the first portion of the lobule, then MIDA becomes the measurement method of choice, even compared with direct tissue sampling of triose-p enrichment (if the latter were possible). This is because the presence of a biosynthetic gradient paralleling a labeling gradient makes the mixed-tissue precursor pool enrichment misleading (i.e., the bulk tissue average will not represent the precursor pool actually used for synthesis). In contrast, combinatorials are based on measurements of the synthesized product molecules themselves. MIDA thereby provides the most effective strategy in principle for measuring biosynthesis when unpredictable or inhomogenous biosynthetic pools are present because only a combinatorial technique can correct for unequal synthetic contributions across the tissue. The simulated effect of a biosynthetic gradient using MIDA versus direct tissue sampling is shown in Table 4 . Even a massive, physiologically unrealistic gradient (e.g., 100-fold from 0.45 to 0.0045 in p) results in almost no underestimation of gluconeogenesis (f glucose = 95.7% of the true value).
The effect of these and other potential complicating factors on MIDA estimates of gluconeogenesis are summarized in Table 4 . These factors aside, in our view, the most important source of potential error in estimating gluconeogenesis by MIDA is analytical. Attention to analytical constraints and avoiding potential problems are critical for accurate use of MIDA in general and particularly for measurement of gluconeogenesis. To calculate p and f glucose , one must be able to measure the M 0 , M 1 , and M 2 isotopomers accurately. This requires sufficient enrichment of each isotopomer to differentiate from natural abundance background and proper performance of the mass spectrometer for each ion. The least abundant mass isotopomer in the case of gluconeogenesis is the M 2 glucose. Our experience and calculations of error sensitivity (6, 18) indicate that the least abundant mass isotopomer must contain at least 0.0050 (0.50%) ME for reliable results. M 2 enrichment is determined by f (not under the investigator's control) and p (under the investigator's control through the infusion rate of 13 C-glycerol). The capacity of the mass spectrometer to measure M 2 and M 1 abundances accurately in the unlabeled standards is also critical because calculation of enrichment requires subtraction of natural abundance values. To avoid systematic errors, the instrument should generate values within ±2% of theoretical values for all mass isotopomers; higher degrees of inaccuracy have extremely large effects on calculated values of gluconeogenesis (e.g., ±5% accuracy results in f glucose values ranging from 68 to 126% of the true value) ( Table 4) . We use ±2% baseline accuracy as a requirement for inclusion of a data run.
Another analytical point is that the amount of sample material in the mass spectrometer source (the total ion abundance) affects the relative abundances measured for different masses (the isotope ratios). This effect, termed "abundance sensitivity" (31, 32) , may be because of factors such as detector nonlinearity and gas-phase bimolecular interactions (e.g., H-extraction). Matching the abundance of the major ion (M 0 ) in all samples (labeled and natural abundance) is therefore essential analytically. Furthermore, this total ion abundance must be set at a value at which all mass isotopomers measured in unlabeled samples fall within the ±2% accuracy range compared with theoretical values. To meet these analytical requirements, preliminary runs of standards and samples are performed, followed by adjustment of injection volumes before making final measurements. An example of acceptable gluconeogenesis data is shown in Table 5 . Note that the total ion abundances are similar for samples and standards; the values for M 1 and M 2 fractional abundances for the standard are close to theoretical values (0.1348 and 0.0256, respectively), and EM 2 -glucose is >0.0050 ME. If any of these features were absent, then the calculation of p and f glucose would be uncertain, and the measurement would be discarded.
To attain adequate M 2 enrichments at f glucose = 20-40%, perturbing the triose-phosphate pool by at least 8-10% is necessary (6, 18) . This can be achieved in human subjects by administration of [2- ) have been shown not to alter EGP (33) . Infusions of labeled glycerol at this rate result in plasma glycerol enrichments of 40-50%, thereby doubling plasma glycerol concentrations (which may help to overcome potential hepatic labeling gradients). The consequence of doubling glycerol delivery to the liver may be to increase the contribution from glycerol to the gluconeogenesis precursor pool and perhaps increase gluconeogenesis modestly (see Table 4 for a simulated effect).
Consistent with the notion that flux from glycogenolysis provides most of the EGP in type 2 diabetes are our results during energy restriction. The reduction in EGP occurred early after energy restriction and resulted entirely from the change in the contribution from glycogenolysis, not gluconeogenesis. This is compatible with previously documented effects of acute starvation to reduce liver glycogen content and glycogenolytic contributions to EGP (6) . That reduction in EGP by 21% could occur by a starvation-induced glycogen depletion mechanism is unlikely a priori if glycogen provided only 12% of EGP at baseline in type 2 diabetes, as was concluded using the NMR method (7) . A primary role for glycogenolysis as a modulating pathway over EGP in type 2 diabetes is consistent with the failure of either reducing gluconeogenesis substrate availability (with ethanol) (34) or increasing gluconeogenesis substrate availability (with fructose) (35) to alter EGP in diabetic subjects, as in healthy control subjects (33, 36) .
Regardless of the metabolic source of EGP, the observation that short-term energy restriction per se reduces fasting hyperglycemia by reducing EGP before changes in body composition occur raises several interesting questions. Perhaps the most obvious from a clinical perspective is how long this energy restriction effect lasts. When the degree of energy restriction was relaxed during the last 10 days of the protocol, no significant changes were evident in weight or FBG. However, EGP increased back to baseline levels entirely because of restoration of the basal contribution from glycogenolysis. The absence of a concomitant rise in FBG at day 20, despite the change in EGP, means that the metabolic clearance of glucose in the postabsorptive state had improved compared with baseline. This may reflect secondary effects such as improved peripheral insulin sensitivity resulting from the prior period of energy restriction; improved peripheral insulin secretion, as has been reported during energy restriction in type 2 diabetes (1,37) ; or an effect on insulin sensitivity of the reduction in hyperglycemia per se. The increased clearance of glucose was not associated with any significant changes in either glucosuria or whole-body carbohydrate oxidation. Thus, the improved clearance represented increased nonoxidative disposal of glucose under the postabsorptive conditions studied. This effect is likely to reside in the muscle, although changes in hepatic uptake of plasma glucose could also contribute. Improvements in glucose disposal rates secondary to improvements in nonoxidative carbohydrate disposal have been reported in response to caloric restriction by Laakso et al. (38) , but glucose disposal was determined by the hyperinsulinemic-euglycemic clamp technique. Hyperinsulinemic-euglycemic clamps are more reflective of postprandial insulin action and may not be directly comparable with our results in the postabsorptive state. In any event, our results suggest that persistent glycemic benefits of energyrestricted diets after reequilibration at a new lower body weight may involve secondary effects (e.g., on insulin secretion or glucose disposal) because the primary action on EGP abates rapidly. Differences in the capacity to invoke such secondary effects may exist among diabetic subjects and contribute to variability in clinical outcomes. This area requires further study.
In response to caloric deprivation, lipid metabolism appears to be affected differently in lean and obese nondiabetic subjects versus our obese diabetic subjects. Lean nondiabetic subjects manifest increased rates of glycerol turnover and whole-body lipid oxidation after energy restriction (39) . Obese nondiabetic subjects manifest no change in glycerol turnover but do increase whole-body lipid oxidation in response to caloric deprivation (40) . In contrast, our obese diabetic subjects showed no increase in either glycerol turnover, NEFA turnover, or whole-body lipid oxidation. Kelley reported a similar response to energy restriction in type 2 diabetes. Individuals with type 2 diabetes require higher insulin levels to suppress lipolysis (41) . Rates of lipolysis were supranormal in our diabetic subjects at baseline compared with nondiabetic subjects studied previously in our laboratory using identical methods (39, 42) . One possible interpretation of our results is that rates of lipolysis were high enough at baseline that whole-body lipid oxidation was already near maximal and therefore did not increase further in response to caloric deprivation. The very low nonprotein respiratory quotients values present at baseline in these diabetic subjects (0.74 ± 0.01) are consistent with this interpretation. This explanation for altered lipid metabolic response to energy restriction in type 2 diabetes is speculative, however, and requires further study.
In conclusion, short-term energy restriction is associated with significant changes in EGP before the occurrence of substantial changes in body weight or composition. The reduction in EGP resulted entirely from a decrease in the contribution from glycogenolysis, whereas absolute rates of gluconeogenesis remained constant. The short-term effects of energy restriction on glucose metabolism in type 2 diabetes therefore appear to represent a starvation or hepatic glycogendepleting mechanism of action. The duration of this effect on EGP is fairly short in that relaxation of the energy restriction without weight gain was associated with a return to baseline values of EGP and glycogenolysis within 10 days. Persistent effects on metabolic clearance of plasma glucose partially preserved the improvements in glycemia despite the return of EGP to baseline. High rates of lipolysis and fat oxidation were present at baseline in these subjects and did not increase further with energy restriction in contrast with the previously reported response of subjects without diabetes (39, 40) .
